Intravesical Injection of Botox for Treating Therapy Refractory Overactive Bladder in Females

Completed

• Conditions: Overactive Bladder Syndrome

• Registration Number: NCT01042119
• Lead Sponsor: University of Zurich

Brief Summary

The neurotoxin Botox (botulinum neurotoxin type A) is shown to be effective in the treatment of therapy refractory overactive bladder syndrome. Our data suggests a longer during efficacy than known from the use in striated muscle.

The aim of our study is to analyze short- and longterm efficacy after Botox treatment and to evaluate risk factors for non-responders and side effects such as urinary retention.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01
• Study First Submitted: 2010-01-04
• Study First Submitted QC: 2010-01-04
• Study First Posted: 2010-01-05
• Status Verified: 2010-06
• Primary Completion: 2010-06
• Study Completion: 2010-06
• Last Update Submitted: 2010-06-23
• Last Update Posted: 2010-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 200

Inclusion Criteria

• intravesical treatment with Botox at our clinic

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
duration of effect of Botox	1 year

Trial Locations

Locations (1)

University Hospital of Zurich, Clinic for Gynaecology; 🇨🇭 Zurich, Switzerland